Staff Profile

I have worked in clinical epidemiology and clinical trial research and management for over 25 years.   My research interests include the epidemiology of leukaemia and lymphoma, disease in the elderly and the design and conduct of randomised controlled clinical trials.   

Roles and Responsibilities

Senior Teacher, Graduate School, Faculty of Medical Sciences

Qualifications

BA Hons - First Class (Newcastle University)

Post-graduate Certificate in Management (Northumbria University) 

MA - Distinction (Durham University)

PhD (Durham University) 

Co-applicant projects:

NIHR – RFPB               EPICC : Extra physiotherapy in critical care                                          

NIHR - HTA                 ANTIC: Antibiotic Treatment for Intermittent Bladder                                                      Catheterisation

NIHR-HTA                   TUBE – Enteral Feeding Post Chemo-radiation                                     

NIHR-PHRP                 VIOLET - Falls Prevention – Visual Impairment 

NIHR - HTA                  ALTAR - Alternatives to Prophylactic Antibiotics for treatment or recurrent UTI                                              

Module Lead MCR8009 (Cert)  – Research Governance & Ethics (elearning)

Lecturer MCR8001 (Cert) – Research Governance & Ethics (face to face)

Module lead MCR8015 (Diploma) – Clinical Trials (elearning)

Lecturer MCR8008 (Diploma) – Clinical Trials (face to face)

Module Lead MCR 8013 (Diploma) – Designing a Research Proposal (elearning)

• Proctor SJ, Wilkinson J, Culligan D, Galloway M, Lucraft HH, Jones G, Mcnally R, Wood KM, Mainou-Fowler T, Watson G, Goodlad JR. Comparative clinical responses of three chemotherapy schedules (VEPEMB, ABVD, CLVPP) in 175 Hodgkin Lymphoma patients over 60ys evaluated as part of the Shield (Hodgkin elderly) Study. In: Annals of Oncology: 11th International Conference on Malignant Lymphoma. 2011, Lugano, Switzerland: Oxford University Press.
• Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010, 115(2), 206-214.
• Proctor SJ, Lennard AL, Jackson GH, Jones GL, Lewis J, Wilkinson J, White J, Sieniawski M, McKay P, Culligan D, Lucraft HH. The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control. Annals of Oncology 2010, 21(2), 426-428.
• Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. Age- and sex-adjusted incidence rates of adults with acute lymphoblastic leukemia (ALL) in the northern part of England Response. Blood 2010, 116(6), 1012-1012.
• Proctor SJ, Wilkinson J, Sieniawski MK. Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future. Critical Reviews in Oncology / Hematology 2009, 71(3), 222-232.
• Sieniawski M, Bhartia S, Wilkinson J, Proctor S. Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone -Rituximab refractory patients. Leukemia and Lymphoma 2009, 50(10), 1726-1730.
• Sieniawski M, Farrow M, Zhao X, Wilkinson J, Mainou-Fowler T, White J, MacIntyre J, Proctor SJ. A Novel Bayesian Prognostic Index for Diffuse Large B-Cell Lymphoma: A New Powerful Tool for Prediction Of Outcome. In: Blood: 51st Annual Meeting of the American Society of Hematology. 2009, New Orleans, LA: American Society of Hematology.
• Sieniawski M, Wilkinson J, Culligan D, Davies J, Goodlad J, Jarrett R, Lennard AL, Lucraft H, Mainou-Fowler T, McKay P, Scott F, Tauro S, White J, Proctor SJ. Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group. In: Blood: 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, California: American Society of Hematology.
• Proctor SJ, Wilkinson J. Hodgkin's lymphoma in the elderly: current status and future directions. Hematology Education 2008, 2(1), 326-331.
• Proctor SJ, Wilkinson J, Mainou-Fowler T, Josting A, Sieniawski M, Wood KM, Jones G, Culligan D, Lucraft H, McNally R, Goodlad JR. SHIELD - Study of Hodgkin lymphoma in the elderly/lymphoma data base: Progress report. In: Annals of Oncology: 10th International Conference on Malignant Lymphoma. 2008, Lugano, Switzerland: Oxford University Press.
• Sieniawski M, Mainou-Fowler T, Wilkinson J, Culligan D, Davison J, Goodlad JR, Jackson GH, Lucraft HH, Lewis J, Lennard A, McKay P, Miekeljohn D, Prescott R, White J, Proctor SJ. The effect of Diffuse Large B-Cell Lymphoma (DLBCL) treatment regimens on survival: a prospective cohort study [Poster]. Annals of Oncology 2008, 19(Supplement 4), 216 no. 451.
• Proctor, SJ, Wilkinson, J. A web-based study concept designed to progress clinical research for 'orphan' disease areas in haematological oncology in the elderly: The SHIELD programme. Critical Reviews in Oncology/Hematology 2007, 61(1), 79-83.
• Proctor SJ, Wilkinson J. Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin's lymphoma. Haematologica Reports 2006, 2(13), 32-34.
• Proctor SJ, Wilkinson J. Extreme Hodgkin's lymphoma: Current problem areas. In: 9th International Conference on Malignant Lymphoma. 2006, Lugano, Switzerland: Annals of Oncology, Oxford University Press.
• Proctor SJ, Wilkinson J, Lucraft H, Taylor PRA, Wood K, Goodlad J. [abstract] International study of Hodgkin's lymphoma in the elderly. European Journal of Haematology 2004, 73, 50-51.
• Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJ, James PW, Goodlad JR. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012, 119(25), 6005-6015.
• Schoenmakers I, Francis RM, McColl E, Chadwick T, Goldberg GR, Harle C, Yarnall A, Wilkinson J, Parker J, Prentice A, Aspray T. Vitamin D supplementation in older people (VDOP): Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000 IU, 24,000 IU or 48,000 IU of vitamin D₃. Trials 2013, 14, 299.
• Brass D, Farr P, Reynolds N, Stocken D, Macdonald C, Wahie S, Weatherhead S, Wilkinson J, Lloyd J, Hill S, Fouweather T, Hampton P. An observer-blinded randomized controlled pilot study comparing localised psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of hand eczema. In: 95th Annual Meeting of the British Association of Dermatologists. 2015, Manchester, UK: Wiley-Blackwell.
• Thomas K, Wright SE, Watson G, Baker C, Stafford V, Wade C, Chadwick TJ, Mansfield L, Wilkinson J, Shen J, Deverill M, Bonner S, Hugill K, Howard P, Henderson A, Roy A, Furneval J, Baudouin SV. Extra Physiotherapy in Critical Care (EPICC) Trial Protocol: a randomised controlled trial of intensive versus standard physical rehabilitation therapy in the critically ill. BMJ Open 2015, 5(5), e008035.
• Stephenson R, Carnell S, Johnson N, Brown R, Wilkinson J, Mundy A, Payne S, Watkin N, N'Dow J, Sinclair A, Rees R, Barclay S, Cook J, Goulao B, MacLennan G, McPherson G, Jackson M, Rapley T, Shen J, Vale L, Norrie J, McColl E, Pickard R. Open urethroplasty versus endoscopic urethrotomy - clarifying the management of men with recurrent urethral stricture (the OPEN trial): study protocol for a randomised controlled trial. Trials 2015, 16, 600.
• Jopson L, Newton JL, Palmer J, Floudas A, Isaacs J, Qian J, Wilkinson J, Trenell M, Blamire A, Howel D, Jones DE. RITPBC: B-Cell Depleting Therapy (rituximab) as a treatment for fatigue in Primary Biliary Cirrhosis: study protocol for a randomised controlled trial. BMJ Open 2015, 5(8), e007985.
• Fisher A, Andreasson A, Chrysos A, Lally J, Mamasoula C, Exley C, Wilkinson J, Qian J, Watson G, Lewington O, Chadwick T, McColl E, Pearce M, Mann K, McMeekin N, Vale L, Tsui S, Yonan N, Simon A, Marczin N, Mascaro J, Dark J. An observational study of Donor Ex Vivo Lung Perfusion in UK Lung Transplantation : DEVELOP-UK. Health Technology Assessment 2016, 20(85).
• Brennand C, von Wilamowitz-Moellendorff A, Dunn S, Wilkinson J, Chadwick T, Ternent L, Oluboyede Y, Wood R, Walton K, Fader M, N'Dow J, Abdel-Fattah M, McClurg D, Little P, Hilton P, Timoney A, Morris N, Thiruchelvam N, Lacombe J, Harrison S, Armstrong H, McColl E, Pickard R. Antibiotic treatment for intermittent bladder catheterisation with once daily prophylaxis (the AnTIC study): Study protocol for a randomised controlled trial. Trials 2016, 17, 276.
• Payne B, Chadwick T, Blamire A, Qian J, Hynes AM, Wilkinson J, Price DA, Anderson K. Neurocognitive and neurometabolic effects of switch from efavirenz to ritonavir-boosted lopinavir. In: 22nd Annual Conference of the British HIV Association (BHIVA). 2016, Manchester: Wiley-Blackwell Publishing Ltd.
• Skelton DA, Bailey C, Howel D, Cattan M, Deary V, Coe D, de Jong LD, Gawler S, Gray J, Lampitt R, Wilkinson J, Adams N. Visually Impaired OLder people's Exercise programme for falls prevenTion (VIOLET): a feasibility study protocol. BMJ Open 2016, 6(8), e011996.
• Davis R, Guglieri M, Hart K, McColl E, Herr B, Martens W, Wilkinson J, Eagle M, King W, Brawn M, McDermott M, Tawil R, Hirtz D, Kirschner J, Bushby K, Griggs RC. Anticipating and overcoming obstacles in setting up NIH funded academic led, international clinical trials in rare disease - learning from for DMD. In: Muscle Study Group Meeting: Experimental Therapeutics Across the Spectrum of Neuromuscular Disease. 2015, Snowbird, Utah, USA: Wiley-Blackwell.
• Guglieri M, Hart K, McColl E, Herr B, Martens W, Wilkinson J, Eagle M, King W, Brawn M, McDermott M, Tawil R, Hirtz D, Kirschner J, Griggs RC, Bushby K. Recruitment in the FOR-DMD study - double-blind randomized trial to optimize steroid regime in Duchenne Muscular Dystrophy (DMD). In: Muscle Study Group Meeting, Experimental Therapeutics Across the Spectrum of Neuromuscular Disease. 2015, Snowbird, Utah, USA: Wiley-Blackwell.
• Jopson L, Newton JL, Howel D, Palmer J, Isaacs J, Qian J, Wilkinson J, Blamire A, Floudas A, Jones DE. RITPBC: B-cell depleting therapy (RITUXIMAB) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. In: 50th Annual meeting of the European Association for the Study of the Liver. 2015, Vienna, Austria: Elsevier.
• McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One 2017, 12(4), e0175717.
• Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Hirtz D, Shieh PB, Straub V, Childs A-M, Ciafaloni E, Butterfield RJ, Horrocks I, Spinty S, Flanigan KM, Kuntz NL, Baranello G, Roper H, Morrison L, Mah JK, Manzur AY, McDonald CM, Schara U, von der Hagen M, Barohn RJ, Campbell C, Darras BT, Finkel RS, Vita G, Hughes I, Mongini T, Pegoraro E, Wicklund M, Wilichowski E, Bryan Burnette W, Howard JF, McMillan HJ, Thangarajh M, Griggs RC. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials 2017, 58, 34-39.
• Payne B, Chadwick TJ, Blamire A, Anderson KN, Parikh J, Qian J, Hynes AM, Wilkinson J, Price DA. Does efavirenz replacement improve neurological function in treated HIV infection?. HIV Medicine 2017, 18(9), 690-695.
• Wright SE, Thomas K, Watson G, Baker C, Bryant A, Chadwick TJ, Shen J, Wood R, Wilkinson J, Mansfield L, Stafford V, Wade C, Furneval J, Henderson A, Hugill K, Howard P, Roy A, Bonner S, Baudouin S. Intensive versus standard physical rehabilitation therapy in the critically ill (EPICC): a multicentre, parallel-group, randomised controlled trial. Thorax 2018, 73(3), 213-221.
• Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Hirtz D, Lochmuller H, Straub V, Ciafaloni E, Shieh PB, Spinty S, Childs A-M, Manzur AY, Morandi L, Butterfield RJ, Horrocks I, Roper H, Flanigan KM, Kuntz NL, Mah JK, Morrison L, Darras BT, von der Hagen M, Schara U, Wilichowski E, Mongini T, McDonald CM, Vita G, Barohn RJ, Finkel RS, Wicklund M, McMillan HJ, Hughes I, Pegoraro E, Bryan Burnette W, Howard JF, Thangarajh M, Campbell C, Griggs RC, Bushby K, Guglieri M. A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial. Trials 2018, 19(1), 291.
• Pickard RS, Chadwick T, Oluboyede Y, Brennand C, von Willamowitz-Moellendorff A, McClurg D, Wilkinson J, Ternent L, Ainsworth H, Walton K, McColl E, Vale L, Wood R, Abdel-Fattah M, Hilton P, Fader M, Harrison S, Larcombe J, Little P, Timoney A, N'Dow J, Armstrong H, Morris N, Walker K, Thiruchelvam N. Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT. Health Technology Assessment 2018, 22(24), i-102.
• Fisher A, Andreasson A, Chrysos A, Lally J, Mamasoula C, Exley C, Wilkinson J, Qian J, Watson G, Lewington O, Chadwick T, McColl E, Pearce M, Mann K, McMeekin N, Vale L, Tsui S, Yonan N, Simon A, Marczin N, Mascaro J, Dark J. An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK. Health Technology Assessment 2016, 20(85), 1-276.